Identification of <scp>DJ</scp>‐1 as a contributor to multidrug resistance in human small‐cell lung cancer using proteomic analysis

Gao, Hong-Yi; Niu, Yucun; Li, Man; Fang, Shun; Guo, Linlang

doi:10.1111/iep.12221

Cited by 24 publications

(14 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PARK7 is highly expressed in patients with NSCLC and has been found to be significantly correlated with the cisplatin resistance and poor survival of patients with NSCLC [105]. PARK7 is associated with the poor survival of patients with SCLC, and markedly decreases the apoptosis of SCLC cells even after treatment with chemotherapeutic drugs, including adriamycin, cisplatin, and etoposide [106]. Proteomic analyses and bioinformatics identified PARK7 as a cisplatin-regulated gene.…”

Section: Park7 Acts As a Marker Of Chemoresistancementioning

confidence: 99%

Novel Insights into PARK7 (DJ-1), a Potential Anti-Cancer Therapeutic Target, and Implications for Cancer Progression

Jin

2020

JCM

View full text Add to dashboard Cite

The expression of PARK7 is upregulated in various types of cancer, suggesting its potential role as a critical regulator of the pathogenesis of cancer and in the treatment of cancer and neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, and Huntington disease. PARK7 activates various intracellular signaling pathways that have been implicated in the induction of tumor progression, which subsequently enhances tumor initiation, continued proliferation, metastasis, recurrence, and resistance to chemotherapy. Additionally, secreted PARK7 has been identified as a high-risk factor for the pathogenesis and survival of various cancers. This review summarizes the current understanding of the correlation between the expression of PARK7 and tumor progression.

show abstract

Section: Park7 Acts As a Marker Of Chemoresistancementioning

confidence: 99%

Novel Insights into PARK7 (DJ-1), a Potential Anti-Cancer Therapeutic Target, and Implications for Cancer Progression

Jin

2020

JCM

View full text Add to dashboard Cite

show abstract

“…Small cell lung cancer (SCLC) accounts for approximately 15% of the total cases of lung cancer (1). Compared with other types of lung cancer, SCLC is usually more sensitive to radiotherapy and chemotherapy, but its diagnosis and treatment are more difficult (3). Although SCLC is sensitive to chemotherapy, it is more likely to develop drug resistance and is highly prone to systemic metastasis (4).…”

Section: Introductionmentioning

confidence: 99%

Identification of candidate genes associated with the pathogenesis of small cell lung cancer via integrated bioinformatics analysis

et al. 2019

View full text Add to dashboard Cite

The pathogenesis of small cell lung cancer (SCLC), a highly metastatic malignant tumor, remains unclear. In the present study, important genes and pathways that are involved in the pathogenesis of SCLC were identified. The following four datasets were downloaded from the Gene Expression Omnibus: GSE60052, GSE43346, GSE15240 and GSE6044. The differentially expressed genes (DEGs) between the SCLC samples and the normal samples were analyzed using R software. The limma package was used for every dataset. The RobustRankAggreg package was used to integrate the DEGs from the four datasets. Functional and pathway enrichment analyses were conducted using the Gene Ontology and Kyoto Encyclopedia of Genes and Genomes databases with FunRich software and R software, respectively. In addition, the protein-protein interaction (PPI) network of the DEGs was constructed using the STRING database and Cytoscape software. Hub genes and significant modules were identified using Molecular Complex Detection in Cytoscape software. Finally, the expression values of hub genes were determined using the Oncomine online database. In total, 412 DEGs were identified following the integration of the four datasets, with 146 upregulated genes and 266 downregulated genes. The upregulated DEGs were primarily enriched in the cell cycle, cell division and microtubule binding. The downregulated DEGs were primarily enriched in the complement and coagulation cascades, the cytokine-mediated signaling pathway and protein binding. Eight hub genes and 1 significant module correlated to the cell cycle pathway were identified based on a subset of the PPI network. Finally, five hub genes were identified as highly expressed in SCLC tissue compared with normal tissue. The cell cycle pathway may be the pathway most closely associated with the pathogenesis of SCLC. NDC80, BUB1B, PLK1, CDC20 and MAD2L1 should be the focus of follow-up studies regarding the diagnosis and treatment of SCLC.

show abstract

“…Proteomic methods have been used widely to identify protein network alterations that may be linked to drugs used to treat lung cancer in terms of sensitivity and resistance [34,35,36,37]. Specifically, two-dimensional gel electrophoresis has been employed to analyze protein expression profiles and identify novel diagnostic, prognostic or predictive biomarkers in these tumors [38,39,40,41,42,43,44]. Due to the complex interactome of HSP90 and the enormous number of cellular processes in which it is involved, the use of proteomic tools for the study of this chaperone and its clients is a common approach [17,45,46,47].…”

Section: Introductionmentioning

confidence: 99%

Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry

Marrugal

Ferrer

Pastor

et al. 2019

Cells

View full text Add to dashboard Cite

Heat shock protein 90 (HSP90) is an important chaperone in lung adenocarcinoma, with relevant protein drivers such as EGFR (epidermal growth factor receptor) and EML4-ALK (echinoderm microtubule-associated protein-like protein4 fused to anaplastic lymphoma kinase) depending on it for their correct function, therefore HSP90 inhibitors show promise as potential treatments for lung adenocarcinoma. To study responses to its inhibition, HSP90 was pharmacologically interrupted by geldanamycin and resorcinol derivatives or with combined inhibition of HSP90 plus HSP70 in lung adenocarcinoma cell lines. Two-dimensional electrophoresis was performed to identify proteomic profiles associated with inhibition which will help to understand the biological basis for the responses. HSP90 inhibition resulted in altered protein profiles that differed according the treatment condition studied. Results revealed 254 differentially expressed proteins after treatments, among which, eukaryotic translation initiation factor3 subunit I (eIF3i) and citrate synthase demonstrated their potential role as response biomarkers. The differentially expressed proteins also enabled signalling pathways involved in responses to be identified; these included apoptosis, serine-glycine biosynthesis and tricarboxylic acid cycle. The proteomic profiles identified here contribute to an improved understanding of HSP90 inhibition and open possibilities for the detection of potential response biomarkers which will be essential to maximize treatment efficacy in lung adenocarcinoma.

show abstract

Identification of DJ‐1 as a contributor to multidrug resistance in human small‐cell lung cancer using proteomic analysis

Cited by 24 publications

References 24 publications

Novel Insights into PARK7 (DJ-1), a Potential Anti-Cancer Therapeutic Target, and Implications for Cancer Progression

Novel Insights into PARK7 (DJ-1), a Potential Anti-Cancer Therapeutic Target, and Implications for Cancer Progression

Identification of candidate genes associated with the pathogenesis of small cell lung cancer via integrated bioinformatics analysis

Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry

Contact Info

Product

Resources

About